The effect of gadopentetate dimeglumine on renal function and early acute kidney injury markers

International Conference and Exhibition on Nephrology & Therapeutics

August 20-22, 2012 Hilton Chicago/Northbrook, USA

Ebru Gok Oguz, Refik Olmaz, Kenan Turgutalp, Onur Ozhan, Mehmet Ali Sungur, Mehmet Horoz and Ahmet Kiykim

Accepted Abstracts: J Nephrol Therapeut

Abstract :

Background: Iodinated radiocontrast media frequently causes acute kidney injury (CIN) in high risk patients. Gadolinium chelates (GC) using in magnetic resonance imaging (MRI) have been considered as non-nephrotoxic contrast materials. But, in some recent articles it has been suggested that GC may have a nephrotoxic potential. Aim: to investigate the effect of gadopentetate dimeglumine (GD) on traditional renal function tests (RFT) and early biomarkers of AKI in the low and high risk patients, and to determine the AKI?s risk factors. Patients and Method: Eighty patients were included the study. Patients are divided into two groups, according to their AKI?s risk factor status (low risk vs high risk). Anthropometric measures and biochemical tests were recorded. Before MRI, traditional renal functional tests (serum creatinine, glomerular filtration rate, urine tests) were assessed. Early biomarkers for AKI (NAG, NGAL, Cystatin C) were also measured. The clinical and laboratory assessments including early biomarkers for AKI are retested at 6, 24 and 72 hours after the contrast (GD)-enhanced MRI. Results: Baseline renal functional capacity was poor in high risk patients (p<0.05). After the MRI, we did not obtained significant change in traditional or early biomarkers for AKI in both groups (p>0.05). We observed no correlation between AKI and risk factor status in high risk patients (p>0.05). Conclusion: The findings demonstrated that GD is not harmful for human kidneys in a short term. GD can be a preferred MR contrast media in high risk patients.